Clinical trials: Female Osteoporosis
Osteoporosis, Postmenopausal
Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women
This study compares the efficacy and safety of generic zoledronic acid (Yigu®) and original zoledronic acid (Aclasta®) in the treatment of postmenopausal osteoporotic women in China.
- Trial name
- NCT03158246
- Testing
- Generic Zoledronic Acid, Original Zoledronic Acid, calcium
- Volunteers
- 466 people
- Sponsor
- Cttq
Postmenopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or…
- Trial name
- NCT02604836
- Testing
- Ibandronate
- Where
- 142 sites in United States
- Volunteers
- 1,711 people
- Sponsor
- Hoffmann-La Roche
Sarcopenia, Falls Patient
Sarcopenia and Risk of Fall in Osteoporotic Postmenopausal Women
The main scope of the present pilot study is to evaluate the possible association between the status of sarcopenia and the risk of fall in osteoporotic postmenopausal women.
- Conditions
- Sarcopenia, Falls Patient, Osteoporosis, Postmenopausal
- Trial name
- Sarcopenia (NCT03382366)
- Testing
- Blood sampling, risk of fall evaluation, and MR acquisition.
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Osteoporosis, HIV
Bone Health in Aging HIV Infected Women
Design: Open-label randomised multicenter international strategic trial of older women on combination antiretroviral therapy (cART) containing tenofovir-emtricitabine (TDF/FTC) with HIV RNA suppression for > 6 months to : 1.
- Conditions
- Osteoporosis, HIV, Menopause
- Trial name
- BEING (NCT02815566)
- Testing
- tenofovir-alafenamide-emtricitabine, tenofovir-emtricitabine
- Where
- 7 sites in Canada, Italy
- Volunteers
- 34 people
- Sponsor
- University Health Network, Toronto
Postmenopausal Osteoporosis, Postmenopause
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
This study will compare the bioequivalence of two new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed formulation of Premarin and medroxyprogesterone, Prempro™.
- Trial name
- NCT00381251
- Testing
- Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Osteoporosis, Osteopenia
The Effect of Exercise in Postmenopausal Women with Low Bone Density
This clinical trial aims to evaluate the effects of a 12 month gym- and home-based exercise program on bone density and falls risk factors in postmenopausal women with low bone density.
- Trial name
- NCT00643331
- Testing
- Exercise
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Osteoporosis
SB: Promoting Bone Health in Women
The goal of this clinical trial is to find out whether multicomponent training works to treat osteoporosis in women. It will also find out about the safety of multicomponent training in this specific population.
- Trial name
- SB (NCT06843486)
- Testing
- Multicomponent Exercise
- Where
- Portugal
- Volunteers
- 40 people
- Sponsor
- Instituto Politécnico de Bragança
Postmenopausal Women
The Relationship Between Bone Mineral Density With Respiratory Functions and Exercise Capacity
If the bone mineral density of a patient with a diagnosis of osteopenia falls further, he develops osteoporosis.Menopause causes many changes in women's bodies in the form of vasomotor, sleep disorders, fatigue, aches and pains…
- Trial name
- NCT05324956
- Testing
- No intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Izmir Bakircay University
Osteoporosis, Postmenopausal, Osteoporotic Fractures
Evaluation of a Decision Analysis Model in the DASH-Osteo Decision Aid.
Fragility fractures, often caused by low bone mineral density, are a major health concern for postmenopausal women. One way to prevent these fractures is by taking medication, but deciding whether to start treatment can be…
- Conditions
- Osteoporosis, Postmenopausal, Osteoporotic Fractures, Diphosphonates, Fracture Risk Assessment
- Trial name
- DASH-Osteo (NCT07120854)
- Testing
- Decision aid with decision analysis model, Decision aid alone, Usual Care
- Where
- Spain
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sarcopenia, Chronic Kidney Diseases
Sarcopenia, Fall and Osteoporosis in Chronic Kidney Disease
This study is a cross-sectional study that wishes to investigate whether there is an increased incidence of sarcopenia in patients with chronic kidney disease compared to the Danish background population.
- Conditions
- Sarcopenia, Chronic Kidney Diseases, Osteoporosis
- Trial name
- NCT04515342
- Testing
- DXA, Muscle strength and function assessment, Blood samples
- Where
- 2 sites in Denmark
- Volunteers
- 140 people
- Sponsor
- Herlev Hospital
Osteoporosis Postmenopausal
Telerehabilitation Versus Traditional Balance Training in Women With Osteoporosis.
Osteoporosis is a silent disease that leads to fractures, postural deformities, and impaired balance, especially in postmenopausal women. In Pakistan, prevalence is high, with 39% of women reported as severely osteoporotic.
- Trial name
- NCT07148479
- Testing
- Telerehabilitation group, Traditional balance training group
- Where
- Pakistan
- Sponsor
- Riphah International University
Breast Cancer, Osteoporosis
Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02
RATIONALE: Gathering information over time from bone density and laboratory tests of women with breast cancer treated with triptorelin and tamoxifen or exemestane may help the study of breast cancer in the future.
- Trial name
- TEXT-Bone (NCT00963417)
- Testing
- laboratory biomarker analysis, dual x-ray absorptiometry
- Where
- 13 sites in Australia, Belgium and 1 more
- Volunteers
- 119 people
- Sponsor
- ETOP IBCSG Partners Foundation
Postmenopausal Osteoporosis
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
- Trial name
- NCT01668589
- Where
- 144 sites in Austria, Belgium and 2 more
- Volunteers
- 1,501 people
- Sponsor
- Amgen
Osteoporosis, Sarcopenia
Evaluation of Balance and Functionality in Postmenopausal Osteoporosis Using Quadriceps Femoris Muscle Thickness, Beyond Thoracic Hyperkyphosis
To determine the impact of thoracic hyperkyphosis, sarcopenia and quadriceps muscle thickness evaluated by ultrasonography (USG) on balance, fall risk and functional parameters in women with postmenopausal osteoporosis, to assess…
- Conditions
- Osteoporosis, Sarcopenia, Ultrasonography, Hyperkyphosis
- Trial name
- NCT06760598
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 103 people
- Sponsor
- Istanbul University - Cerrahpasa
Postmenopausal Osteoporosis
Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study in approximately 201 postmenopausal women.
- Trial name
- NCT00918749
- Testing
- 150 mg, 75 mg, 100 mg
- Where
- 6 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Warner Chilcott
Osteoporosis
RECONFIRM - Study of AGN1 LOEP in Patients with Osteoporosis
The research will be conducted as a prospective, post-market, multi-center study within Europe. The maximum number of subjects to be treated is 150 across up to 20 sites. This will be a non-randomized and open-label study.
- Trial name
- NCT05202678
- Testing
- AGN1 LOEP
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- AgNovos Healthcare, LLC
Osteoporosis
Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
A randomized, open label study to assess the safety and effectiveness of Denosumab, administered every 6 months and Actonel ® (Risedronate), administered monthly in post menopausal women transitioned from weekly or daily…
- Trial name
- NCT00919711
- Testing
- Actonel®, Denosumab
- Volunteers
- 870 people
- Sponsor
- Amgen
Osteoporosis, Sarcopenia
Effect of Creatine Supplementation and Exercise on Bone Health
Osteoporosis is an important health problem, costing the Canadian health care system over $2 billion per year. Loss of bone mineral and bone fragility is especially prevalent in postmenopausal women.
- Trial name
- NCT02047864
- Testing
- Creatine monohydrate
- Where
- 2 sites in Canada
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Osteoporosis, Postmenopausal
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.
- Trial name
- MORE (NCT00670319)
- Testing
- Raloxifene HCL
- Where
- 25 sites in United States, Argentina and 23 more
- Volunteers
- 7,705 people
- Sponsor
- Eli Lilly and Company
Osteopenic Women
Bone Quality Lyon Orleans
QUALYOR is a prospective study on the predictive value for fragility fracture of various new techniques assessing bone quality, among postmenopausal women with low bone mass.
- Trial name
- QUALYOR (NCT01150032)
- Testing
- Bone quality complementary exams
- Where
- 2 sites in France
- Volunteers
- 1,605 people
- Sponsor
- Hospices Civils de Lyon